Serán Bioscience Announces Investment by Vivo Capital
Serán Bioscience Announces Investment by Vivo Capital A majority investment by Vivo Capital, a healthcare investment firm headquartered in Silicon Valley, will fund the expansion of Serán's service offering, the doubling of clean room capacity by year-end, and the development and construction a new commercial scale cGMP manufacturing facility by the end of 2022. News provided by Share this article Share this article BEND, Ore., Jan. 6, 2021 /PRNewswire/ -- Serán Bioscience today announced that healthcare investment firm Vivo Capital has made a majority investment in Serán alongside Sera...
Source: prnewswire.com